explore -WSS

explore

author：Wikipedia 2025-09-30 00:50:46 - browse：38

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Liver decline slowed by off

WSS

As a primary care physician, here's how I hope to partner with AI

H5N1 virus can be tracked in retail milk, scientists say

Reports of telehealth's death have been greatly exaggerated

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Intellia plays down concerns on accidental germline transmission

CDC says it’s too soon to assess risk posed by Covid subvariant

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Activists slam private health insurers over coverage restrictions

DeSantis wants to import drugs. Biden’s FDA blasted his plan

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Former Pear Therapeutics executives start new VC firm

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Roche's accidental data boosts hopes for anti

ChatGPT in medicine: STAT answers readers' burning questions

UnitedHealth argues against case alleging wrongful AI care denials

Tori Bowie and the unacceptable rates of Black maternal death

National associations that represent hospice owe an apology

hotspot

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Making the case for fair compensation in clinical trials

Health officials lay out plans to cope with respiratory virus season

At flashy new research hub, AstraZeneca lays out ambitious growth goals

focus

Wikipedia

focus

hotspot